| dc.contributor.author |
Manosuthi W. |
|
| dc.contributor.author |
Sungkanuparph S. |
|
| dc.contributor.author |
Ruxrungtham K. |
|
| dc.contributor.author |
Prasithsirikul W. |
|
| dc.contributor.author |
Athichathanabadi C. |
|
| dc.contributor.author |
Tantisiriwat W. |
|
| dc.contributor.author |
Bowonwatanuwong C. |
|
| dc.contributor.author |
Chumpathat N. |
|
| dc.contributor.author |
Chaovavanich A. |
|
| dc.date.accessioned |
2021-04-05T04:32:04Z |
|
| dc.date.available |
2021-04-05T04:32:04Z |
|
| dc.date.issued |
2008 |
|
| dc.identifier.issn |
15254135 |
|
| dc.identifier.other |
2-s2.0-39049117418 |
|
| dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/14896 |
|
| dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-39049117418&doi=10.1097%2fQAI.0b013e318157b0da&partnerID=40&md5=9c6cb1be2c5626aefcfeb310a21297cf |
|
| dc.description.abstract |
[No abstract available] |
|
| dc.subject |
atazanavir |
|
| dc.subject |
proteinase inhibitor |
|
| dc.subject |
ritonavir |
|
| dc.subject |
RNA directed DNA polymerase inhibitor |
|
| dc.subject |
saquinavir |
|
| dc.subject |
virus RNA |
|
| dc.subject |
atazanavir |
|
| dc.subject |
oligopeptide |
|
| dc.subject |
proteinase inhibitor |
|
| dc.subject |
pyridine derivative |
|
| dc.subject |
ritonavir |
|
| dc.subject |
saquinavir |
|
| dc.subject |
adult |
|
| dc.subject |
aminotransferase blood level |
|
| dc.subject |
blood sampling |
|
| dc.subject |
CD4 lymphocyte count |
|
| dc.subject |
clinical article |
|
| dc.subject |
controlled study |
|
| dc.subject |
DNA polymorphism |
|
| dc.subject |
drug blood level |
|
| dc.subject |
drug efficacy |
|
| dc.subject |
drug safety |
|
| dc.subject |
drug tolerability |
|
| dc.subject |
dyslipidemia |
|
| dc.subject |
female |
|
| dc.subject |
high performance liquid chromatography |
|
| dc.subject |
human |
|
| dc.subject |
Human immunodeficiency virus infection |
|
| dc.subject |
hyperbilirubinemia |
|
| dc.subject |
letter |
|
| dc.subject |
low drug dose |
|
| dc.subject |
male |
|
| dc.subject |
practice guideline |
|
| dc.subject |
priority journal |
|
| dc.subject |
salvage therapy |
|
| dc.subject |
side effect |
|
| dc.subject |
steady state |
|
| dc.subject |
treatment duration |
|
| dc.subject |
treatment outcome |
|
| dc.subject |
virus resistance |
|
| dc.subject |
article |
|
| dc.subject |
drug administration |
|
| dc.subject |
drug combination |
|
| dc.subject |
Drug Administration Schedule |
|
| dc.subject |
Drug Therapy, Combination |
|
| dc.subject |
HIV Infections |
|
| dc.subject |
HIV Protease Inhibitors |
|
| dc.subject |
Humans |
|
| dc.subject |
Oligopeptides |
|
| dc.subject |
Pyridines |
|
| dc.subject |
Ritonavir |
|
| dc.subject |
Saquinavir |
|
| dc.title |
Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir |
|
| dc.type |
Letter |
|
| dc.rights.holder |
Scopus |
|
| dc.identifier.bibliograpycitation |
Journal of Acquired Immune Deficiency Syndromes. Vol 47, No.1 (2008), p.127-129 |
|
| dc.identifier.doi |
10.1097/QAI.0b013e318157b0da |
|